[go: up one dir, main page]

PE20090315A1 - Composiciones de fenilalanina amoniaco liasa procariotica y metodos para usar composiciones de la misma - Google Patents

Composiciones de fenilalanina amoniaco liasa procariotica y metodos para usar composiciones de la misma

Info

Publication number
PE20090315A1
PE20090315A1 PE2008000889A PE2008000889A PE20090315A1 PE 20090315 A1 PE20090315 A1 PE 20090315A1 PE 2008000889 A PE2008000889 A PE 2008000889A PE 2008000889 A PE2008000889 A PE 2008000889A PE 20090315 A1 PE20090315 A1 PE 20090315A1
Authority
PE
Peru
Prior art keywords
compositions
variant
liasa
ammonia
phenylalanine
Prior art date
Application number
PE2008000889A
Other languages
English (en)
Inventor
Michel Claude Vellard
Paul Andrew Fitzpatrick
Emil D Kakkis
Daniel J Wendt
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39868905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090315(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of PE20090315A1 publication Critical patent/PE20090315A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA VARIANTE DE FENILALANINA AMONIACO-LIASA (PAL) PROCARIOTICA TAL COMO LA VARIANTE PAL ANABAENA VARIABILIS (AvPAL) EN EL QUE UNO O MAS RESIDUOS DE CISTEINA HAN SIDO SUSTITUIDOS POR UNO O MAS RESIDUOS DE SERINA EN LAS POSICIONES 64, 318, 503 Y 565 EN LA ID SEC NO. 11, Y QUE ADEMAS COMPRENDE UN POLIMERO SOLUBLE EN AGUA TAL COMO POLIETILENGLICOL. DICHA VARIANTE AvPAL TIENE MAYOR ACTIVIDAD DE CONVERSION DE FENILALANINA Y UNA INMUNOGENICIDAD REDUCIDA. SE REFIERE TAMBIEN A UNA COMPOSICION QUE CONTIENE DICHA VARIANTE AvPAL PEGILADA SIENDO UTIL EN EL TRATAMIENTO DE ENFERMEDADES PRODUCIDAS POR UNA DEFICIENCIA EN LA FENILALANINA HIDROXILASA (PAH), FENILCETONURIA, HIPERFENILALANINEMIA
PE2008000889A 2007-05-25 2008-05-23 Composiciones de fenilalanina amoniaco liasa procariotica y metodos para usar composiciones de la misma PE20090315A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/807,227 US7534595B2 (en) 2006-06-12 2007-05-25 Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof

Publications (1)

Publication Number Publication Date
PE20090315A1 true PE20090315A1 (es) 2009-03-19

Family

ID=39868905

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000889A PE20090315A1 (es) 2007-05-25 2008-05-23 Composiciones de fenilalanina amoniaco liasa procariotica y metodos para usar composiciones de la misma

Country Status (29)

Country Link
US (1) US7534595B2 (es)
EP (2) EP2152868B1 (es)
JP (1) JP5670183B2 (es)
KR (2) KR20150038753A (es)
CN (1) CN101842482B (es)
AR (2) AR066716A1 (es)
AU (1) AU2008263190B2 (es)
BR (1) BRPI0811267B8 (es)
CA (1) CA2687450C (es)
CL (1) CL2008001497A1 (es)
CY (2) CY1116894T1 (es)
DK (1) DK2152868T3 (es)
EA (1) EA018443B1 (es)
ES (1) ES2551315T3 (es)
HR (1) HRP20151268T1 (es)
HU (2) HUE025784T2 (es)
IL (1) IL202132A (es)
LT (1) LTC2152868I2 (es)
LU (1) LUC00133I2 (es)
MX (1) MX2009012453A (es)
MY (1) MY151413A (es)
NL (1) NL301011I2 (es)
NO (1) NO2019037I1 (es)
PE (1) PE20090315A1 (es)
PL (1) PL2152868T3 (es)
PT (1) PT2152868E (es)
SI (1) SI2152868T1 (es)
TW (1) TWI418633B (es)
WO (1) WO2008153776A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7537923B2 (en) * 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
US20110201022A1 (en) * 2008-07-30 2011-08-18 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
EP3025728B1 (en) 2010-02-04 2018-08-08 BioMarin Pharmaceutical Inc. Method for purifying prokaryotic phenylalanine ammonia-lyase variants
AU2013295621A1 (en) * 2012-07-27 2015-03-12 University Of North Texas Genetically modified probiotic for the treatment of phenylketonuria (PKU) disease
ES2890955T3 (es) * 2013-04-18 2022-01-25 Codexis Inc Polipéptidos de fenilalanina amoníaco liasa modificados
BR112016011195A2 (pt) 2013-11-18 2017-09-19 Rubius Therapeutics Inc Células eritroides enucleadas e seus métodos de fabricação, composição farmacêutica e seu uso, uso de uma população de células eritroides, biorreator, mistura de células e dispositivo médico
WO2015153102A1 (en) 2014-04-01 2015-10-08 Rubius Therapeutics, Inc. Methods and compositions for immunomodulation
US9605252B2 (en) 2014-04-16 2017-03-28 Codexis, Inc. Engineered tyrosine ammonia lyase
KR102702200B1 (ko) 2014-12-22 2024-09-02 코덱시스, 인코포레이티드 인간 알파-갈락토시다제 변이체
TW202440903A (zh) * 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（一）
BR112019001532A2 (pt) 2016-07-26 2019-09-10 Biomarin Pharm Inc proteínas de capsídeo de vírus adenoassociado inovadoras
WO2018043546A1 (ja) * 2016-08-30 2018-03-08 三菱ケミカル株式会社 変異型酵素の製造方法及び変異型アルコールアシルトランスフェラーゼ
CN106497905A (zh) * 2016-12-14 2017-03-15 江南大学 一株鱼腥藻来源的苯丙氨酸脱氨酶的突变体
CN110573175A (zh) * 2017-02-13 2019-12-13 科德克希思公司 工程化苯丙氨酸氨裂合酶多肽
CN107653275A (zh) * 2017-10-30 2018-02-02 安徽工程大学 D‑苯丙氨酸的制备方法
CN108004225B (zh) * 2017-12-19 2020-05-08 江南大学 一种成团泛菌来源的苯丙氨酸氨基变位酶的突变体
CN113164762A (zh) 2018-05-09 2021-07-23 生物马林药物股份有限公司 苯丙酮尿症的治疗方法
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
US10900055B2 (en) * 2018-06-12 2021-01-26 Codexis, Inc. Engineered tyrosine ammonia lyase
JP2021531749A (ja) * 2018-07-12 2021-11-25 コデクシス， インコーポレイテッド 操作されたフェニルアラニンアンモニアリアーゼポリペプチド
WO2020123286A1 (en) 2018-12-14 2020-06-18 Codexis, Inc. Engineered tyrosine ammonia lyase
MX2021007552A (es) 2018-12-20 2021-08-11 Codexis Inc Variantes de alfa-galactosidasa humana.
CN110456056A (zh) * 2019-07-22 2019-11-15 浙江大学 一种新生儿苯丙酮尿症无创筛查试纸的制备方法
AU2020336468A1 (en) 2019-08-30 2022-03-03 Societe Des Produits Nestle S.A. Engineered lipase variants
AU2020408066A1 (en) 2019-12-20 2022-06-30 Codexis, Inc. Engineered acid alpha-glucosidase variants
KR20220137057A (ko) 2020-02-04 2022-10-11 코덱시스, 인코포레이티드 조작된 류신 데카르복실라제
EP4107281A4 (en) * 2020-02-19 2024-08-14 Trustees of Tufts College PROCESS FOR PRODUCING AMINO ACID-AMMONIAC LYASE ENZYMES AND ENZYMES OBTAINED THEREFROM
TW202144575A (zh) 2020-04-03 2021-12-01 美商拜奧馬林製藥公司 使用ａａｖ及治療調配物之苯酮尿症治療
US11767519B2 (en) 2020-08-28 2023-09-26 Codexis, Inc. Engineered amylase variants
US11959108B2 (en) 2020-08-28 2024-04-16 Codexis, Inc. Engineered protease variants
EP4341394A4 (en) 2021-05-19 2025-04-09 BioMarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia lyase and methods for treating adolescent patients
WO2022246126A1 (en) 2021-05-21 2022-11-24 Codexis, Inc. Engineered methionine gamma lyase variants
US20250000957A1 (en) * 2021-09-16 2025-01-02 Arcturus Therapeutics, Inc. Compositions and methods for treating phenylketonuria
CN117417925A (zh) * 2022-07-18 2024-01-19 浙江泽科塔生物医药有限公司 Pal变体、包含该pal变体的药物组合物以及用于制备该pal变体的方法
CN118931888A (zh) * 2023-05-09 2024-11-12 重庆派金生物科技有限公司 苯丙氨酸裂解酶突变体及其偶联物或其药学上可接受的盐
GB202307239D0 (en) 2023-05-15 2023-06-28 Evox Therapeutics Ltd Gene therapies for Phenylketonuria
CN116478975B (zh) * 2023-06-16 2023-09-01 苏州优信合生技术有限公司 高活性苯丙氨酸解氨酶突变体及其表达菌株
US20250161466A1 (en) 2023-11-17 2025-05-22 Biomarin Pharmaceutical Inc. Conjugates of phenylalanine ammonia-lyase and poegma and methods for their use

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4252822A (en) 1979-12-26 1981-02-24 Children's Hospital Medical Center Method for treating phenylketonuria
US4562151A (en) 1983-09-06 1985-12-31 Monsanto Company Stabilization of L-phenylalanine ammonia-lyase enzyme
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
ES2184756T3 (es) 1992-11-19 2003-04-16 Anticancer Inc Uso de metioninasa como agente antitumoral en quimioterapia antimetionina.
JP4007516B2 (ja) 1992-12-04 2007-11-14 ロバーツ，ジョゼフ 遺伝学的に操作されたグルタミナーゼ、および抗ウイルスと抗ガン治療におけるその使用
US5849535A (en) 1995-09-21 1998-12-15 Genentech, Inc. Human growth hormone variants
DK75593D0 (es) 1993-06-25 1993-06-25 Novo Nordisk As
CA2185671A1 (en) * 1994-03-15 1995-09-21 Prizm Pharmaceuticals, Inc. Heparin-binding growth factors for gene therapy and anterior eye disorders
CU22585A1 (es) * 1995-11-17 1999-11-03 Centro Inmunologia Molecular Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune.
US6548644B1 (en) 1997-03-10 2003-04-15 Immunex Corporation Site protected protein modification
US6183738B1 (en) 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
US5981239A (en) 1997-09-24 1999-11-09 Great Lakes Chemical Corp. Synthesis of optically active phenylalanine analogs using Rhodotorula graminis
CA2315944A1 (en) * 1997-12-24 1999-07-08 Diatech Pty. Ltd. Bifunctional molecules
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US6461849B1 (en) 1998-10-13 2002-10-08 Novozymes, A/S Modified polypeptide
US6403312B1 (en) 1998-10-16 2002-06-11 Xencor Protein design automatic for protein libraries
US6686164B1 (en) 1998-10-30 2004-02-03 Novozymes A/S Low allergenic protein variants
IL138990A0 (en) 1999-02-12 2001-11-25 Biostream Inc Matrices for drug delivery and methods for making and using the same
IL150109A0 (en) * 1999-12-09 2002-12-01 Chiron Corp Method for administering a cytokine to the central nervous system and the lymphatic system
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
US6939541B2 (en) 2000-04-14 2005-09-06 University Of South Carolina Cloning, overexpression and therapeutic use of bioactive histidine ammonia lyase
US6967097B2 (en) 2000-07-24 2005-11-22 Pcbu Services, Inc. Phenylalainine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same
ATE545703T1 (de) * 2000-07-25 2012-03-15 Immunomedics Inc Multivalentes zielbindendes protein
WO2002026028A2 (en) * 2000-09-26 2002-04-04 The Regents Of The University Of California Characterization of phenylalanine ammonia-lyase (pal) gene in wounded lettuce
CN1268641C (zh) * 2000-11-10 2006-08-09 普罗蒂奥制药公司 载脂蛋白类似物
IL162811A0 (en) 2002-02-26 2005-11-20 Du Pont Method for the recombination of genetic elements
EP2351770A1 (en) * 2002-07-17 2011-08-03 Cytos Biotechnology AG Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
WO2004044169A2 (en) 2002-11-14 2004-05-27 The Scripps Research Institute Crystalline form of fatty acid amine hydrolase (faah)
JP2007537710A (ja) * 2003-06-11 2007-12-27 ワイス 血小板糖タンパク質ＩＢα改変体融合ポリペプチドおよびその使用法
FR2868318B1 (fr) * 2004-04-01 2012-11-16 Commissariat Energie Atomique Antigene tat stabilise et ses applications pour la vaccination anti-vih
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
US7553653B2 (en) 2004-09-17 2009-06-30 Biomarin Pharmaceutical Inc. Variants and chemically-modified variants of phenylalanine ammonia-lyase
WO2006099207A2 (en) 2005-03-10 2006-09-21 Diversa Corporation Lyase enzymes, nucleic acids encoding them and methods for making and using them
US7534595B2 (en) 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
WO2008069958A2 (en) 2006-12-01 2008-06-12 The Salk Institute For Biological Studies Substrate switched ammonia lyases and mutases
US7537923B2 (en) 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof

Also Published As

Publication number Publication date
KR101603796B1 (ko) 2016-03-17
CN101842482B (zh) 2014-10-22
WO2008153776A1 (en) 2008-12-18
TW200902052A (en) 2009-01-16
EA200970980A1 (ru) 2010-04-30
LUC00133I2 (es) 2020-07-16
LTPA2019517I1 (lt) 2019-10-25
IL202132A0 (en) 2010-06-16
HRP20151268T1 (hr) 2015-12-18
CN101842482A (zh) 2010-09-22
NO2019037I1 (no) 2019-10-16
IL202132A (en) 2017-06-29
TWI418633B (zh) 2013-12-11
CA2687450A1 (en) 2008-12-18
SI2152868T1 (sl) 2015-12-31
BRPI0811267B8 (pt) 2021-05-25
WO2008153776A8 (en) 2009-07-30
DK2152868T3 (en) 2015-11-16
AU2008263190A1 (en) 2008-12-18
CY2019039I1 (el) 2020-05-29
MX2009012453A (es) 2010-01-25
NL301011I2 (nl) 2020-05-13
PT2152868E (pt) 2015-11-13
US20080008695A1 (en) 2008-01-10
HUS1900049I1 (hu) 2019-11-28
JP2010529835A (ja) 2010-09-02
CL2008001497A1 (es) 2009-01-09
LTC2152868I2 (lt) 2020-09-25
BRPI0811267B1 (pt) 2020-11-10
KR20100024437A (ko) 2010-03-05
EP2152868B1 (en) 2015-09-02
AU2008263190B2 (en) 2014-04-17
CA2687450C (en) 2019-03-26
BRPI0811267A2 (pt) 2014-10-07
KR20150038753A (ko) 2015-04-08
PL2152868T3 (pl) 2016-01-29
EP2152868A1 (en) 2010-02-17
EP2657335A1 (en) 2013-10-30
AR110834A2 (es) 2019-05-08
CY1116894T1 (el) 2017-04-05
ES2551315T3 (es) 2015-11-18
MY151413A (en) 2014-05-30
LUC00133I1 (es) 2019-10-16
US7534595B2 (en) 2009-05-19
EA018443B1 (ru) 2013-08-30
NL301011I1 (nl) 2019-10-16
AR066716A1 (es) 2009-09-09
HK1135141A1 (zh) 2010-05-28
HUE025784T2 (en) 2016-05-30
JP5670183B2 (ja) 2015-02-18
CY2019039I2 (el) 2020-05-29

Similar Documents

Publication Publication Date Title
PE20090315A1 (es) Composiciones de fenilalanina amoniaco liasa procariotica y metodos para usar composiciones de la misma
PE20090605A1 (es) Composiciones de fenilalanina amoniaco-liasa procariotica y metodos del tratamiento del cancer usando composiciones de la misma
AR050030A1 (es) Composiciones blanqueadoras dentales y sistemas para su administracion
PE20090711A1 (es) Region constante de anticuerpo mutante
WO2006136607A3 (de) Verwendung von hydrophobin-polypeptiden sowie konjugaten aus hydrophobin-polypeptiden mit wirk- oder effektstoffen und ihre herstellung sowie deren einsatz in der kosmetik
WO2006091780A3 (en) Nanoparticulate formulations of docetaxel and analogues thereof
BRPI0513310A (pt) análogos de tetrapeptìdeo
MY159820A (en) Macrocyclic hepatitis c serine protease inhibitors
MX2010004571A (es) Composiciones y metodos que comprenden peptidos y proteasas de aminoacidos basicos.
AR050717A1 (es) Composiciones farmaceuticas
MX2011012015A (es) Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.
NZ596254A (en) Cleanser compositions and methods for using the same comprising linalool, hinokitiol, diol and surfactant
UA100851C2 (ru) Средство для борьбы с паразитами на животных
NZ707160A (en) A stable aqueous composition comprising human insulin or an analogue or derivative thereof
MY161595A (en) Oral care compositions
PH12012501620A1 (en) Oral care compositions
TNSN07477A1 (en) Use of sanglifehrin in hcv
IL208609A0 (en) Composition and process for the destruction of organophosphorus and/or organosulphur pollutants
AR079750A2 (es) Comprimidos bucodispersables y metodo de fabricacion
CO6382109A2 (es) Formulación de depósito de octreotida con niveles de exposición constantemente altos
MY165041A (en) Composition for improving brain function and method for improving brain function
CL2007003190A1 (es) Compuestos derivados de arilsulfonil-pirrolidinas; procedimiento de obtencion; composicion farmaceutica; y uso en la prevencion o tratamiento de enfermedades tales como psicosis, depresion, alzheimer, entre otras.
WO2008048121A3 (en) Macrocyclic cysteine protease inhibitors and compositions thereof
WO2007138562A3 (en) Concentrated perfume compositions
ATE503491T1 (de) Verbesserte anthraximpfstoffe und abgabeverfahren

Legal Events

Date Code Title Description
FG Grant, registration